2022 MIPS Reporting Highlights through RISE



The ACR's RISE Qualified Clinical Data Registry (QCDR) is celebrating a successful 2022 MIPS submission period! As a reminder, the performance threshold for 2022 MIPS reporting was at an all-time high of 75 MIPS points. This means that practices must receive at least 75 total MIPS points to avoid a negative payment adjustment in the 2024 payment year.

In addition, new for 2022, clinicians were automatically re-weighted for the Promoting Interoperability [PI] category if they were a part of a small practice with 15 or fewer clinicians billing under the practice's TIN. For these clinicians who chose to have PI automatically re-weighted, their Quality category weight increased to 40% and their Improvement Activities (IA) category weight increased to 30%; they did not receive a score for PI.

Here are highlights and reporting outcomes from the 2022 MIPS submissions through RISE that may serve as a valuable resource as you plan to report via <u>Traditional MIPS</u> or the <u>Advancing Rheumatology</u> <u>Patient Care MIPS Value Pathway (MVP)</u> through RISE for the 2023 performance year.

2022 MIPS Performance Threshold

Performance (neutral payment) threshold = 75.00 points

Additional performance threshold = 89.00 points

Note: Final year for an additional performance threshold/additional MIPS adjustment for exceptional performance

Reporting Statistics

- Number of Practices
 - -95 practices reported for MIPS via the RISE registry (41% of RISE practices)
- Number of Clinicians
 - -502 clinicians reported for MIPS via the RISE registry (7.49% increase from last year's 2021 MIPS submissions)
- Submission Type
 - -56 group submissions
 - -60 individual submissions

Quality Performance Category Details

■ Average preliminary Quality score: 27.02 points/30 points

Note: Total possible score increases with approved category reweighting.

- Most Popular Measures Reported:
 - 1. QPP39: Screening for Osteoporosis for Women Aged 65-85 Years of Age
 - QPP176: Tuberculosis Screening Prior to First Course of Biologic and/or Immune Response Modifier Therapy

2022 MIPS Reporting Highlights through RISE



- 3. QPP177: Rheumatoid Arthritis (RA): Periodic Assessment of Disease Activity
- 4. ACR15: Safe Hydroxychloroquine Dosing
- 5. OPP178: Rheumatoid Arthritis (RA): Functional Status Assessment
- 6. ACR10: Hepatitis B Safety Screening
- 7. QPP130: Documentation of Current Medications in the Medical Record
- 8. ACR14: Gout: Serum Urate Target
- 9. QPP128: Preventive Care and Screening: Body Mass Index (BMI) Screening and Follow-Up Plan
- 10. ACR12: Disease Activity Measurement for Patients with PsA

Promoting Interoperability (PI) Performance Category Details

■ Average preliminary PI score: 26.81 points/25 points

Note: Total possible score increases with approved category reweighting.

Improvement Activities (IA) Performance Category Details

■ Average preliminary IA score: 26.04 points/15 points

Note: Total possible score increases with approved category reweighting.

■ Most Popular Activities Reported:

- 1. IA_AHE_6 Provide Education Opportunities for New Clinicians
- 2. IA_BE_1 Use of certified EHR to capture patient reported outcomes
- 3. IA BE 4 Engagement of patients through implementation of improvements in patient portal
- 4. IA BMH 2 –Tobacco use
- 5. IA_CC_1 Implementation of use of specialist reports back to referring clinician or group to close referral loop
- 6. IA_EPA_1 Provide 24/7 Access to MIPS Eligible Clinicians or Groups Who Have Real-Time Access to Patient's Medical Record
- 7. IA EPA 2 –Use of telehealth services that expand practice access
- 8. IA_PSPA_29 –Consulting Appropriate Use Criteria (AUC) Using Clinical Decision Support when Ordering Advanced Diagnostic Imaging
- 9. IA PSPA 31 Patient Medication Risk Education
- 10. IA PSPA 6 Consultation of the Prescription Drug Monitoring program

Practices are strongly encouraged to review the <u>CMS QPP website</u>, <u>CMS QPP Resource Library</u>, and the ACR RISE monthly QPP Pointers newsletter to stay up to date on how you're impacted by the <u>Quality Payment Program (QPP)</u>, <u>Traditional MIPS</u>, and the <u>MIPS Value Pathway (MVP)</u> reporting requirements per performance year.

If you have any questions about MIPS submissions through RISE, please contact us at RISE@rheumatology.org.